Long-term outcomes of the Japanese hemodialysis patients with prostate cancer detected by prostate-specific antigen screening.
We investigated the long-term outcomes of the Japanese hemodialysis patients with prostate cancer detected by prostate-specific antigen (PSA) screening. Clinical data of 646 male hemodialysis patients aged 55 years or older who started yearly PSA testing in the period from January 1, 2004 to December 31, 2012 and were followed until December 31, 2017 were analyzed retrospectively. The median follow-up period was 10.4 years. Nineteen (2.9%) patients were diagnosed with prostate cancer, of whom one patient died of the disease. Androgen-deprivation therapy (ADT) was selected for primary prostate cancer treatment in 17 (89.5%) of these 19 patients. Of six prostate cancer patients who underwent primary ADT (PADT) and died of other causes, three died of infectious disease, each one died of cardiovascular disease, liver cancer, and chronic renal failure. No significant difference was observed in regard to overall survival between the prostate cancer patients with PADT and non-prostate cancer patients. Prognosis of hemodialysis patients who were diagnosed with prostate cancer during yearly PSA screening examination and mainly treated with ADT was favorable without increasing cardiovascular events. This result indicates that PSA screening may be useful for detection and management of prostate cancer even in hemodialysis patients. J. Med. Invest. 68 : 42-47, February, 2021.
['Yokota|Narushi|N|', 'Takahashi|Masayuki|M|', 'Nishitani|Masaaki|M|', 'Minakuchi|Jun|J|', 'Kanayama|Hiro-Omi|HO|']
D000726:Androgen Antagonists D018931:Antineoplastic Agents, Hormonal D055088:Early Detection of Cancer D006801:Humans D007564:Japan D008297:Male D017430:Prostate-Specific Antigen D011471:Prostatic Neoplasms D006435:Renal Dialysis D012189:Retrospective Studies
hemodialysis prostate cancer PSA